



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Margaret E. Black
Application No. : 09/173,463
Filed : October 14, 1998
For : THYMIDINE KINASE MUTANTS AND FUSION PROTEINS
HAVING THYMIDINE KINASE AND GUANYLATE KINASE
ACTIVITIES

Examiner : Christian L. Fronda
Art Unit : 1652
Docket No. : 60117-4
Date : July 11, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENTS UNDER 37 C.F.R. 1.821 and 1.825


Commissioner for Patents:

I, Dr. Jane E.R. Potter, Esq., do hereby declare that the amendment to the sequence listing included in the replacement sheets and CRF comprising the amended sequence listing are supported by the application as filed. In addition, the replacement CRF copy and paper copies of the sequence listing are identical.

Several Thymidine Kinase mutants are described in the application as filed, but were never assigned sequence identifiers. New SEQ ID NOs. 122-172 are added by way of this amendment. As support for this amendment, the attached table identifies where all of the application's sequences are described, including the newly added sequences. In addition, a substitute Specification (clean and redline version) is filed

herewith, incorporating the newly added sequence identifiers. No new matter is contained in the replacement sheets and CRF comprising the amended Sequence Listing.

Respectfully submitted,
Margaret Black
DAVIS WRIGHT TREMAINE LLP

By 
Jane E. R. Potter
Registration No. 33,332

1201 Third Avenue, Suite 2200
Seattle, WA 98101-3045
Phone: (206) 622-3150
Facsimile: (206) 757-7700



Support in Specification and Figures for Sequences

SEQ. NO.	Brief Description	Where described in Specification as filed
1	Nucleotides in the open reading frame of HSVTK-1	Figure 23
2	primer	Page 40
3	Primer	Page 40
4	Primer	Page 41
5	Primer	Page 41
6	Primer	Page 43, 52
7	Primer	Page 43, 52
8	Primer	Page 44
9	Primer	Page 51
10	Primer	Page 51
11	Primer	Page 54
12	wild type nucleic acid sequence (fragment)	Figure 3, page 63 (Table II)
13	wild type amino acid sequence (fragment)	Figure 3, page 63 (Table II)
14	TKF 36 (HSVTK Mutant) nucleic acid sequence (fragment) (A168S)	page 63 (Table II), pages 62-67
15	TKF 36 (HSVTK Mutant) amino acid sequence (fragment) (A168S)	page 63 (Table II), pages 62-67
16	TKF 41 (HSVTK Mutant) nucleic acid sequence (fragment)	page 63 (Table II), pages 62, and 67-68
17	TKF 41 (HSVTK Mutant) amino acid sequence (fragment) (P165S/A167G/L170Q/A174V)	page 63 (Table II), pages 62, and 67-68
18	TKF 52 (HSVTK Mutant) nucleic acid sequence (fragment)	page 63 (Table II), pages 62, and 64
19	TKF 52 (HSVTK Mutant) amino acid sequence (fragment) (A168T)	page 63 (Table II), pages 62, and 64
20	TKF 99 (HSVTK Mutant) nucleic acid sequence (fragment)	page 63 (Table II), pages 62, and 67-68
21	TKF 99 (HSVTK Mutant) amino acid sequence (fragment) (C171L/A174T)	page 63 (Table II), pages 62, and 67-68
22	TKI 208 (HSVTK Mutant) nucleic acid sequence (fragment)	Figure 3, Page 46, page 63 (Table II), pages, 62, and 67-68
23	TKI 208 (HSVTK Mutant) amino acid sequence (fragment) (L170V)	Figure 3, Page 46, page 63 (Table II), pages, 62, and 67-68
24	MB126 – Primer	Page 75
25	MB127 – Primer	Page 75
26	Primer	Page 89
27	Primer	Page 89
28	Primer – DMO 512	Page 89
29	Primer – DMO 513	Page 89
30	Primer – DMO 514	Page 89
31	Primer – DMO 515	Page 89
32	Primer	Page 89
33	Primer	Page 90

Support in Specification and Figures for Sequences

34	Primer – DMO 592	Page 91
35	Primer – DMO 594	Page 91
36	Primer – DMO 595	Page 91
37	Primer – DMO 674	Page 91
38	Primer – DMO 675	Page 91
39	Primer – DMO 731	Page 91
40	Primer – DMO 732	Page 91
41	Primer – DMO 676	Page 91
42	Primer – DMO 604	Page 92
43	Primer – DMO 605	Page 92
44	Primer – DMO 606	Page 92
45	Primer – DMO 607	Page 92
46	Vector Fusion Peptide	Page 92-93
47	Nucleotides randomized in the LIF-All Library	Figure 14
48	Nucleotide sequence representative of a human guanylate kinase	Figure 24
49	Deduced Amino Acid sequence representative of a human guanylate kinase	Figure 24
50	Nucleotide sequence representative of a murine guanylate kinase	Figure 25
51	Deduced Amino Acid sequence representative of a murine guanylate kinase	Figure 25
52	Primer – DMO 748	Page 91
53	Primer – DMO 749	Page 91
54	Primer – DMO 750	Page 91
55	TKF 105 – HSVTK Mutant – nucleic acid	Figure 3, Page 46
56	TKF 105 – HSVTK Mutant - amino acid (L170I)	Figure 3, Page 46
57	TKF 2 - HSVTK Mutant – nucleic acid	Figures 3-4, pages 49-50
58	TKF 2 - HSVTK Mutant – amino acid (P165H/A167S/A174V)	Figures 3-4, pages 49-50
59	Wild Type nucleic acid fragment	Figure 17
60	Wild type amino acid fragment	Figure 17
61	Nucleotide changes shown in fragment of in mutant 30	Figure 17, page 77
62	Nucleotide changes shown in fragment of in mutant 51	Figure 17
63	Nucleotide changes shown in fragment of in mutant 75	Figure 17
64	Nucleotide changes shown in fragment of in mutant 84	Figure 17, page 77
65	Nucleotide changes shown in fragment of in mutant 132	Figure 17
66	Nucleotide changes shown in fragment of in mutant 197	Figure 17, pages 77-78
67	Nucleotide changes shown in fragment of in mutant	Figure 17, pages 77-78

Support in Specification and Figures for Sequences

	226	
68	Nucleotide changes shown in fragment of in mutant 312	Figure 17
69	Nucleotide changes shown in fragment of in mutant 340	Figure 17, pages 77-78
70	Nucleotide changes shown in fragment of in mutant 411	Figure 17, pages 77-78
71	Amino acid substitutions (selected clones)	Figure 15
72	Amino acid substitutions (selected clones)	Figure 15
73	Amino acid substitutions (selected clones)	Figure 15
74	Amino acid substitutions (selected clones)	Figure 15
75	Amino acid substitutions (selected clones)	Figure 15
76	Amino acid substitutions (selected clones)	Figure 15
77	Amino acid substitutions (selected clones)	Figure 15
78	Amino acid substitutions (selected clones)	Figure 15
79	Amino acid substitutions (selected clones)	Figure 15
80	Amino acid substitutions (selected clones)	Figure 15
81	Amino acid substitutions (selected clones)	Figure 15
82	Amino acid substitutions (selected clones)	Figure 15
83	Amino acid substitutions (selected clones)	Figure 15
84	Amino acid substitutions (selected clones)	Figure 15
85	Amino acid substitutions (selected clones)	Figure 15
86	Amino acid substitutions (selected clones)	Figure 15
87	Amino acid substitutions (selected clones)	Figure 15
88	Amino acid substitutions (selected clones)	Figure 15
89	Amino acid substitutions (unselected clones)	Figure 15
90	Amino acid substitutions (unselected clones)	Figure 15
91	Amino acid substitutions (unselected clones)	Figure 15
92	Amino acid substitutions (unselected clones)	Figure 15
93	Amino acid substitutions (unselected clones)	Figure 15
94	Amino acid substitutions (unselected clones)	Figure 15
95	Amino acid substitutions (unselected clones)	Figure 15
96	Amino acid substitutions (unselected clones)	Figure 15
97	Amino acid substitutions (unselected clones)	Figure 15
98	Amino acid substitutions (unselected clones)	Figure 15
99	Amino acid substitutions (unselected clones)	Figure 15
100	Amino acid substitutions (unselected clones)	Figure 15
101	Amino acid substitutions (unselected clones)	Figure 15
102	Amino acid substitutions (unselected clones)	Figure 15
103	Amino acid substitutions (unselected clones)	Figure 15
104	Amino acid substitutions (unselected clones)	Figure 15
105	Wild type TK (amino acid fragment)	Page 84
106	Second Generation Mutant SR11 (amino acid fragment)	Pages 84-87, and 96
107	Second Generation Mutant SR26 (amino acid	Pages 84-87, and 96

Support in Specification and Figures for Sequences

	fragment)	
108	Second Generation Mutant SR39 (amino acid fragment)	Pages 84-87, and 96
109	Second Generation Mutant SR4 (amino acid fragment)	Page 84
110	Second Generation Mutant SR15 (amino acid fragment)	Page 84
111	Second Generation Mutant SR32 (amino acid fragment)	Page 84
112	Second Generation Mutant SR53 (amino acid fragment)	Pages 84-85
113	primer	Page 87
114	semi randomized oligonucleotides used to generate second generation of mutants	Figure 21
115	semi randomized oligonucleotides used to generate second generation of mutants	Figure 21
116	DMO-1860 - primer	Figure 22, page 88
117	DMO-1861 – primer	Figure 22, page 88
118	DMO-1893 – primer	Figure 22, page 88
119	DMO-1894 – primer	Figure 22, page 88
120	DMO-1895 – primer	Figure 22, page 88
121	DMO-1896 - primer	Figure 22, page 88
122*	HSVTK Mutant 30 (fragment) – amino acid (A152V)	Figure 18, pages 77 and 96
123*	HSVTK Mutant 51 (fragment) – amino acid	Figure 18
124*	HSVTK Mutant 75 (fragment) – amino acid	Figure 18
125*	HSVTK Mutant 84 (fragment) – amino acid (A156S)	Figure 18, page 77
126*	HSVTK Mutant 132 (fragment) – amino acid	Figure 18
127*	HSVTK Mutant 197 (fragment) – amino acid	Figure 18
128*	HSVTK Mutant 226 (fragment) – amino acid	Figure 18
129*	HSVTK Mutant 302 (fragment) – amino acid	Figure 18
130*	HSVTK Mutant 340 (fragment) – amino acid	Figure 18
131*	HSVTK Mutant 411 (fragment) – amino acid	Figure 18
132*	Anticipated Amino Acid Substitutions	Figure 21
133*	Anticipated Amino Acid Substitutions (showing stop at position 170)	Figure 21
134*	Wild type – amino acid translation	Amino acid translation of Figure 23
135*	HSVTK Mutant 30 – amino acid (A152V)	Figure 18, pages 77 and 96
136*	HSVTK Mutant 86 – amino acid	Figure 18
137*	HSVTK Mutant 197 – amino acid	Figure 18
138*	HSVTK Mutant 226 – amino acid	Figure 18
139*	HSVTK Mutant 340 – amino acid	Figure 18
140*	HSVTK Mutant 411 – amino acid	Figure 18

Support in Specification and Figures for Sequences

141*	HSVTK Mutant – amino acid (P155A/F161V)	Page 18, page 55 (Table 1B), page 56 (Table II), pages 57, 59- 61, and 69
142*	HSVTK Mutant – amino acid (P155Q/F161I)	Page 55 (Table 1B)
143*	HSVTK Mutant – amino acid (P155Q/D162E)	Page 55 (Table 1B)
144*	HSVTK Mutant – amino acid (P155R/D162E)	Page 55 (Table 1B)
145*	HSVTK Mutant – amino acid (P155R/D162G)	Page 55 (Table 1B)
146*	HSVTK Mutant – amino acid (P155T/D162E)	Page 55 (Table 1B)
147*	HSVTK Mutant – amino acid (F161I/R163H)	Page 55 (Table 1B), page 56 (Table II), pages 57 and 59
148*	HSVTK Mutant – amino acid (F161I/P165R)	Page 55 (Table 1B)
149*	HSVTK Mutant – amino acid (F161N/P165S)	Page 55 (Table 1B)
150*	HSVTK Mutant – amino acid (D162Y/R163C)	Page 55 (Table 1B)
151*	HSVTK Mutant – amino acid (D162N/H164K)	Page 55 (Table 1B)
152*	HSVTK Mutant – amino acid (D162E/H164N)	Page 55 (Table 1B)
153*	HSVTK Mutant – amino acid (R163P/H164Q)	Page 55 (Table 1B), page 56 (Table II), pages 57 and 59
154*	HSVTK Mutant – amino acid (H164Q/P165L)	Page 55 (Table 1B)
155*	HSVTK Mutant – amino acid (P155Q/D162E/P165L)	Page 55 (Table 1B)
156*	HSVTK Mutant – amino acid (P155A/R163P/P165T)	Page 55 (Table 1B)
157*	HSVTK Mutant – amino acid (D162N/R163S/H164N/P165A)	Page 55 (Table 1B)
158*	HSVTK Mutant – amino acid (P155A/F161C)	Page 18
159*	HSVTK Mutant – amino acid (P155A/D162E)	Page 18
160*	HSVTK Mutant – amino acid (I160L/F161L/A168V/L169M)	Page 18
161*	HSVTK Mutant – amino acid (F161L/A168V/L169Y/L170C)	Page 18
162*	HSVTK Mutant – amino acid (F161I)	Page 56 (Table II), pages 57, and 59-61
163*	HSVTK Mutant – amino acid (F161C)	Page 56 (Table II), pages 57, and 59-61
164*	HSVTK Mutant – amino acid (F161L)	Page 56 (Table II), pages 59-60
165*	HSVTK Mutant – amino acid – TKF 75 (A167S)	Page 49, Figure 4
166*	HSVTK Mutant – amino acid – TKF 56 (A174V)	Page 49, Figure 4
167*	HSVTK Mutant – amino acid – TKF 440 (P165A)	Page 49, Figure 4
168*	HSVTK Mutant – amino acid (D162G)	Page 59
169*	HSVTK Mutant – amino acid (D162E)	Figure 7, pages 59-60
170*	HSVTK Mutant – amino acid (R163P)	Page 60
171*	HSVTK Mutant – amino acid (H164Q)	Page 60
172*	Primer – DMO 1358	Page 87

*new sequence